US-based immuno-oncology company Neon Therapeutics has begun enrolment for its inaugural trial of NEO-PV-01 to treat cancer.
The company lead programme NEO-PV-01 has been designed as a personalised neoantigen vaccine, a result of initial clinical trials developed collaboratively by the Broad Institute and Dana-Farber Cancer Institute.
It can be specifically administered to patients based on the neoantigen mutations unique to each patient’s tumour.
The trial has enrolled its first patient at the University of Texas MD Anderson Cancer Center and is expected to include a total of 90 patients from ten sites across the US.
During the trial, the patients will undergo an initial biopsy and be administered with a vaccine suited to each patient’s tumour.
The patients will also be administered with nivolumab in combination with NEO-PV-01.
Neon Therapeutics CEO Hugh O’Dowd said: “Enrolling our first patient in this groundbreaking study is a critical milestone for the company and for patients.
“We are assessing the safety and efficacy of this unique individualised product, alongside demonstrating the feasibility and practicality of this sophisticated supply chain.”
Neon Therapeutics previously conducted its first multicentre Phase Ib clinical trial of NEO-PV-01 combined with PD-1 immune checkpoint inhibitor, Opdivo, to treat patients with measurable metastatic melanoma, non-small-cell lung and bladder cancer.